Pneumococcal conjugate vaccine: Review of cost-effectiveness studies in Australia, North America and Europe

Expert Review of Pharmacoeconomics and Outcomes Research

Volumn 8, Issue 4, 2008, Pages 373-393

  Ray, G Thomas ^a  

^a DIVISION OF RESEARCH   (United States)

Author keywords

Cost effectiveness; Economics; Pneumococcal; Review; Vaccine

Indexed keywords

ANTIBIOTIC AGENT; PNEUMOCOCCUS VACCINE;

ACUTE OTITIS MEDIA; ANTIBIOTIC RESISTANCE; AUSTRIA; BACTERIAL COLONIZATION; BACTERIAL MENINGITIS; BACTERIAL TRANSMISSION; CHILDHOOD MORTALITY; CLINICAL TRIAL; COST BENEFIT ANALYSIS; COST CONTROL; COST EFFECTIVENESS ANALYSIS; COST OF ILLNESS; DISABILITY; DISEASE SEVERITY; DRUG COST; DRUG EFFICACY; ECONOMIC EVALUATION; EUROPE; EVIDENCE BASED MEDICINE; FINANCIAL MANAGEMENT; HEALTH CARE SYSTEM; HEALTH ECONOMICS; HERD IMMUNITY; HUMAN; IMMUNOGENICITY; INCIDENCE; INFECTION RISK; LABORATORY TEST; LIFE EXPECTANCY; MORBIDITY; NORTH AMERICA; PHYSICAL EXAMINATION; PRACTICE GUIDELINE; PREVENTIVE HEALTH SERVICE; PUBLIC HEALTH SERVICE; QUALITY OF LIFE; REVIEW; RISK REDUCTION; SEROTYPE; SOCIAL STATUS; SOCIOECONOMICS; STREPTOCOCCUS INFECTION; STREPTOCOCCUS PNEUMONIA; STREPTOCOCCUS PNEUMONIAE; THORAX RADIOGRAPHY;

EID: 55149112787     PISSN: 14737167     EISSN: 17448379     Source Type: Journal    
DOI: 10.1586/14737167.8.4.373     Document Type: Review

References (66)

1. Whitney CG, Moore MR. Direct and indirect effectiveness and safety of pneumococcal conjugate vaccine in practice. In: Pneumococcal Vaccines. The Impact of Conjugate Vaccine. Siber GR, Klugman KP, Makela PH (Eds). ASM Press, DC, USA, 353-368 (2008).
2. Zimmerman RK, Jackson RE. Vaccine policy decisions: tension between science, cost-effectiveness and consensus? Am. Fam. Physician 63(10), 1919-1923 (2001).
3. Jewett P. President's column - news update. American Academy of Pediatrics California. 2000(4), Chapter 1 (2000).
4. Ray GT. Pneumococcal conjugate vaccine: economic issues of the introduction of a new childhood vaccine. Expert Rev. Vaccines 1(1), 65-74 (2002).
5. Hueston WJ, Mainous AG 3rd, Brauer N. Predicting cost-benefits before programs are started: looking at conjugate vaccine for invasive pneumococcal infections. J. Community Health 25(1), 23-33 (2000).
6. Lieu TA, Ray GT, Black SB et al. Projected cost-effectiveness of pneumococcal conjugate vaccination of healthy infants and young children. JAMA 283(11), 1460-1468 (2000).
7. Weycker D, Richardson E, Oster G. Childhood vaccination against pneumococcal otitis media and pneumonia: an analysis of benefits and costs. Am. J. Manag. Care 6(10 Suppl.), S526-S535 (2000).
8. De Wals P, Petit G, Erickson LJ et al. Benefits and costs of immunization of children with pneumococcal conjugate vaccine in Canada. Vaccine 21(25-26), 3757-3764 (2003).
9. Ess SM, Schaad UB, Gervaix A, Pinosch S, Szucs TD. Cost-effectiveness of a pneumococcal conjugate immunisation program for infants in Switzerland. Vaccine 21(23), 3273-3281 (2003).
10. Claes C, Graf von der Schulenburg JM. Cost-effectiveness of pneumococcal vaccination for infants and children with the conjugate vaccine PnC-7 in Germany. Pharmacoeconomics 21(8), 587-600 (2003).
11. McIntosh ED, Conway P, Willingham J, Lloyd A. The cost-burden of paediatric pneumococcal disease in the UK and the potential cost-effectiveness of prevention using 7-valent pneumococcal conjugate vaccine. Vaccine 21(19-20), 2564-2572 (2003).
12. Lebel MH, Kellner JD, Ford-Jones EL et al. A pharmacoeconomic evaluation of 7-valent pneumococcal conjugate vaccine in Canada. Clin. Infect. Dis. 36(3), 259-268 (2003).
13. Asensi F, De Jose M, Lorente M et al. A pharmacoeconomic evaluation of seven-valent pneumococcal conjugate vaccine in Spain. Value Health 7(1), 36-51 (2004).
14. Wisloff T, Abrahamsen TG, Bergsaker MA et al. Cost-effectiveness of adding 7-valent pneumococcal conjugate (PCV-7) vaccine to the Norwegian childhood vaccination program. Vaccine 24(29-30), 5690-5699 (2006).
15. Moore D, Bigham M, Patrick D. Modelling the costs and effects of a universal infant immunization program using conjugated pneumococcal vaccine in British Columbia. Can. Commun. Dis. Rep. 29(11), 97-104 (2003).
16. Bos JM, Rumke H, Welte R, Postma MJ. Epidemiologic impact and cost-effectiveness of universal infant vaccination with a 7-valent conjugated pneumococcal vaccine in the Netherlands. Clin. Ther. 25(10), 2614-2630 (2003).
17. Melegato A, Edmunds WJ. Cost-effectiveness analysis of pneumococcal conjugate vaccination in England and Wales Vaccine 22(31-32), 4203-4214 (2004).
18. Navas E, Salleras L, Gisbert R et al. Cost-benefit and cost-effectiveness of the incorporation of the pneumococcal 7-valent conjugated vaccine in the routine vaccination schedule of Catalonia (Spain). Vaccine 23(17-18), 2342-2348 (2005).
19. Salo H, Sintonen H, Pekka NJ et al. Economic evaluation of pneumococcal conjugate vaccination in Finland. Scand. J. Infect. Dis. 37(11-12), 821-832 (2005).
20. Butler JR, McIntyre P, MacIntyre CR et al. The cost-effectiveness of pneumococcal conjugate vaccination in Australia. Vaccine 22(9-10), 1138-1149 (2004).
21. Marchetti M, Colombo GI. Cost-effectiveness of universal pneumococcal vaccination for infants in Italy. Vaccine 23(37), 4565-4576 (2005).
22. Beutels P, Thiry N, Van Damme P. Convincing or confusing? Economic evaluations of childhood pneumococcal conjugate vaccination - a review (2002-2006). Vaccine 25(8), 1355-1367 (2007).
23. Black S, Shinefield H, Fireman B et al. Efficacy, safety and immunogenicity of heptavalent pneumococcal conjugate vaccine in children. Northern California Kaiser Permanente Vaccine Study Center Group. Pediatr. Infect. Dis. J. 19(3), 187-195 (2000).
24. Eskola J, Kilpi T, Palmu A et al. Efficacy of a pneumococcal conjugate vaccine against acute otitis media. N. Engl. J. Med. 344(6), 403-409 (2001).
25. Fireman B, Black SB, Shinefield HR et al. Impact of the pneumococcal conjugate vaccine on otitis media. Pediatr. Infect. Dis. J. 22(1), 10-16 (2003).
26. Black SB, Shinefield HR, Ling S et al. Effectiveness of heptavalent pneumococcal conjugate vaccine in children younger than five years of age for prevention of pneumonia. Pediatr Infect. Dis. J. 21(9), 810-815 (2002).
27. Centers for Disease Control and Prevention. Notice to readers: updated recommendations for use of pneumococcal conjugate vaccine: reinstatement of third dose. MWWR Morb. Mortal Wkly Rep. 53(26), 589-590 (2004).
28. Lipscomb J, Weinstein MC, Torrance GW. Time preference. In: Cost Effectiveness in Health and Medicine. Gold MR, Siegel JE, Russell LB, Weinstein MC (Eds.). Oxford University Press, NY, USA, 214-246 (1996).
29. Viscusi WK. Discounting health effects for medical decisions. In: Valuing Health Care: Costs, Benefit, and Effectiveness of Phamraceuticals and Other Medical Technologies. Sloan FA (Ed.). Cambridge University Press, Cambridge, UK, 125-147 (1995).
30. Torgerson DJ, Raftery J. Economic notes. Discounting. BMJ 319(7214), 914-915 (1999).
31. Gravelle H, Brouwer W, Niessen L, Postma M, Rutten F. Discounting in economic evaluations: stepping forward towards optimal decision rules. Health Econ. 16(3), 307-317 (2007).
32. Birks S. Discounting health effects in pharmacoeconomic evaluations: current controversies. Pharmacoeconomics 24(12), 1273-1274 (2006).
33. Bos JM, Postma MJ, Annemans L. Discounting health effects in pharmacoeconomic evaluations: current controversies. Pharmacoeconomics 23(7), 639-649 (2005).
34. Lazaro A. Theoretical arguments for the discounting of health consequences: where do we go from here? Pharmacoeconomics 20(14), 943-961 (2002).
35. Brouwer WB, Niessen LW, Postma MJ, Rutten FF. Need for differential discounting of costs and health effects in cost effectiveness analyses. BMJ 331(7514), 446-448 (2005).
36. Gold MR, Patrick DL, Torrance GW et al. Identifying and valuing outcomes. In: Cost-Effectiveness in Health and Medicine. Gold MR, Seigel JE, Russell LB Weinstein MC (Eds). Oxford University Press, NY, USA, 82-134 (1996).
37. Prosser LA, Ray GT, O'Brien M et al. Preferences and willingness to pay for health States prevented by pneumococcal conjugate vaccine. Pediatrics 113(2), 283-290 (2004).
38. Cheng AK, Rubin HR, Powe NR et al. Cost-utility analysis of the cochlear implant in children. JAMA 284(7), 850-856 (2000).
39. Bennett JE, Sumner W, Downs SM, Jaffe DM. Parents' utilities for outcomes of occult bacteremia. Arch. Pediatr. Adolesc. Med. 154(1), 43-48 (2000).
40. Oostenbrink R, A Moll HA, Essink-Bot ML. The EQ-5D and the Health Utilities Index for permanent sequelae after meningitis: a head-to-head comparison. J. Clin. Epidemiol. 55(8), 791-799 (2002).
41. Oh PI, Macrov P, Pritchard D et al. A cost-utility analysis of second-line antibiotics in the treatment of acute otitis media in children. Clin. Ther. 18(1), 160-182 (1996).
42. Pepper PV, Owens DK. Cost-effectiveness of the pneumococcal vaccine in the United States Navy and Marine Corps. Clin. Infect. Dis. 30(1), 157-164 (2000).
43. Black S, Shinefield H, Baxter R et al. Postlicensure surveillance for pneumococcal invasive disease after use of heptavalent pneumococcal conjugate vaccine in Northern California Kaiser Permanente. Pediatr. Infect. Dis. J. 23(6), 485-489 (2004).
44. Centers for Disease Control and Prevention. Direct and indirect effects of routine vaccination of children with 7-valent pneumococcal conjugate vaccine on incidence of invasive pneumococcal disease - United States, 1998-2003. MMWR Morb. Mortal. Wkly. Rep. 54(36), 893-897 (2005).
45. Lexau CA, Lynfield R, Danila R et al. Changing epidemiology of invasive pneumococcal disease among older adults in the era of pediatric pneumococcal conjugate vaccine. JAMA 294(16), 2043-2051 (2005).
46. Grijalva CG, Poehling KA, Nuorti JP et al. National impact of universal childhood immunization with pneumococcal conjugate vaccine on outpatient medical care visits in the United States. Pediatrics 118(3), 865-873 (2006).
47. Grijalva CG, Nuorti JP, Arbogast PG et al. Decline in pneumonia admissions after routine childhood immunisation with pneumococcal conjugate vaccine in the USA: a time-series analysis. Lancet 369(9568), 1179-1186 (2007).
48. O'Brien KL, Dagan R, Makela PH. Nasopharyngeal carriage. In: Pneumococcal Vaccines: The Impact of Conjugate Vaccine. Siber GR, Klugman KP, Makela PH (Eds). ASM Press, DC, USA, 279-300 (2008).
49. Ray GT, Whitney CG, Fireman BH, Ciuryla V, Black SB. Cost-effectiveness of pneumococcal conjugate vaccine: evidence from the first 5 years of use in the United States incorporating herd effects. Pediatr. Infect. Dis. J. 25(6), 494-501 (2006).
50. McIntosh ED, Conway P, Willingham J, Hollingsworth R, Lloyd A. Pneumococcal pneumonia in the UK - how herd immunity affects the cost-effectiveness of 7-valent pneumococcal conjugate vaccine PCV). Vaccine 23(14), 1739-1745 (2005).
51. Black SB, Shinefield HR, Ray PM, Fireman BH. Efficacy of heptavalent conjugate pneumococcal vaccine (Wyeth Lederle) in 37,000 infants and children: impact on pneumonia, otitis media, and an update on invasive disease results of the Northern California Kaiser Permanente efficcacy trial. Presented at: 38th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy. CA, USA, 24-27 September 1998 (Abstract 1398).
52. Luce BR, Manning WG, Siegel JE, Lipscomb J. Estimating costs in cost-effectiveness analysis. In: Cost-effectiveness in Health and Medicine. Gold MR, Siegel JE, Russell LB, Weinstein MC (Eds). Oxford University Press, NY, USA, 176-213 (1996).
53. Garber AM, Weinstein MC, Torrance GW, Kamlet MS. Theoretical foundations of cost-effectiveness analysis. In: Cost Effectiveness in Health and Medicine. Gold MR, Seigel JE, Russell LB, Weinstein MC (Eds). Oxford University Press, NY, USA, 25-53 (1996).
54. Lieu TA, Cochi SL, Black SB et al. Cost-effectiveness of a routine varicella vaccination program for US children. JAMA 271(5), 375-381 (1994).
55. Margolis HS, Coleman PJ, Brown RE et al. Prevention of hepatitis B virus transmission by immunization. An economic analysis of Current recommendations. JAMA 274(15), 1201-1208 (1995).
56. Stone PW, Teutsch S, Chapman RH et al. Cost-utility analyses of clinical preventive services: published ratios, 1976-1997. Am. J. Prev. Med. 19(1), 15-23 (2000).
57. Ubel PA, Hirth RA, Chernew ME, Fendrick AM. What is the price of life and why doesn't it increase at the rate of inflation? Arch. Intern. Med. 163(14), 1637-1641 (2003).
58. Grosse SD. Assessing cost-effectiveness in healthcare: history of the $50,000 per QALY threshold. Expert Rev. Pharmacoeconomics Outcomes Res. 8(2), 165-178 (2008).
59. Birch S, Gafni A. The biggest bang for the buck or bigger bucks for the bang: the fallacy of the cost-effectiveness threshold. J. Health Serv. Res. Policy. 11(1), 46-51 (2006).
60. Birch S, Gafni A. Information created to evade reality (ICER): things we should not look to for answers. Pharmacoeconomics 24(11), 1121-1131 (2006).
61. Gafni A, Birch S. Incremental cost-effectiveness ratios (ICERs): the silence of the lambda. Soc. Sci. Med. 62(9), 2091-2100 (2006).
62. Zhou F, Kyaw MH, Shefer A, Winston CA, Nuorti JP. Health care utilization for pneumonia in young children after routine pneumococcal conjugate vaccine use in the United States. Arch. Pediatr Adolesc. Med. 161(12), 1162-1168 (2007).
63. Zhou F, Shefer A, Kong Y, Nuorti JP. Trends in acute otitis media-related health care utilization by privately insured young children in the United States, 1997-2004. Pediatrics 121(2), 253-260 (2008).
64. Poehling KA, Szilagyi PC, Grijalva CG et al. Reduction of frequent otitis media and pressure-equalizing tube insertions in children after introduction of pneumococcal conjugate vaccine. Pediatrics 119(4), 707-715 (2007).
65. Sinha A, Levine O, Knoll MD, Muhib F, Lieu TA. Cost-effectiveness of pneumococcal conjugate vaccination in the prevention of child mortality: an international economic analysis. Lancet 369(9559), 389-396 (2007).
66. Sinha A, Ray GT. Pharmacoeconomics of pneumococcal conjugate vaccines. In: Pneumococcal Vaccines: The Impact of Conjugate Vaccine Siber C, Klugman KP, Makela PH (Eds). ASM Press, DC, USA, 387-403 (2008).